Abstract
Chemotherapy is one of the important and effective options for cancer treatment in the past decades. Although the response rate of initial chemotherapy is considerably high in certain types of cancers, such as ovarian cancer and lung cancer, the patients frequently suffer from chemoresistance and recurrence of disease. Recent genome-wide studies have shown that the large number of long non-coding RNAs (lncRNAs) are transcribed from the human genome and involved in many biological processes including carcinogenesis. They aberrantly regulate variety of cell functions, such as cell cycle, apoptosis, autophagy, and metabolisms, which are associated with chemosensitivity. Therefore, understanding the biological and clinical impacts of lncRNAs on tumor behavior and its potential as a predictive biomarker for chemotherapy effectiveness is highly desired. In this review, we classify the major mechanisms of lncRNA-related chemoresistance and provide theoretical evidences for targeting lncRNAs in certain types of cancers that may open up new therapeutic paradigm for cancer treatment.
Similar content being viewed by others
Abbreviations
- ABC:
-
ATP binding cassette
- ABCB1, ABCC1, ABCC2 and ABCG2:
-
ATP binding cassette subfamily B member 1, C member 1, C member 2 and G member 2
- AMPK:
-
AMP-activated protein kinase
- Ara-C:
-
cytarabine
- ATG:
-
autophagy-related gene
- ATM:
-
ataxia-telangiectasia-mutated
- ATR:
-
ataxia telangiectasia and Rad3-related
- BAD:
-
Bcl-2-associated death promoter
- BAK:
-
Bcl-2 homologous antagonist killer
- BAX:
-
Bcl-2-associated X protein members
- Bcl-2:
-
B-cell lymphoma 2
- Bcl-XL:
-
B-cell lymphoma-extra large
- BDNF:
-
brain derived neurotrophic factor
- BID:
-
BH3 interacting domain death agonist
- BIK:
-
BCL2 interacting killer
- BLACAT1:
-
lncRNA- bladder cancer associated transcript 1
- CDDP:
-
cisplatin
- CDH1:
-
cadherin 1
- CDK1 and CDK4:
-
cyclin dependent kinase 1 and 4
- ceRNA:
-
competing endogenous RNA
- CHK1and CHK2:
-
checkpoint kinases 1 and 2
- CREB:
-
cAMP response element-binding protein
- CRNDE::
-
ncRNA- colorectal neoplasia differentially expressed
- CSC:
-
cancer stem cell
- CTX:
-
Cyclophosphamide
- DANCR:
-
differentiation antagonizing non-protein coding RNA
- DDSR1:
-
DNA damage-sensitive lncRNA1
- DNA-PKcs:
-
DNA-dependent protein kinase catalytic subunit
- DOX:
-
doxorubicin
- DSB:
-
double-strand break
- E2F1:
-
E2F transcription factor 1
- E2F7:
-
E2F transcription factor 7
- EGOT:
-
Ai-lncRNA-eosinophil granule ontogeny transcript
- EMT:
-
epithelial-to-mesenchymal transition
- ERBB4:
-
receptor tyrosine-protein kinase erbB-4
- EZH2:
-
enhancer of zeste 2 polycomb repressive complex 2 subunit
- 5-FU:
-
Fluorouracil
- GBCDRlnc1:
-
gallbladder cancer drug resistance-associated lncRNA1PGK1
- H3K27me3:
-
histone H3 lysine 27 trimethylation
- HCC:
-
hepatocellular carcinoma
- HMGA1:
-
high-mobility group protein A 1
- hnRNPH1:
-
heterogeneous nuclear ribonucleoprotein H1
- hnRNPK:
-
heterogeneous nuclear ribonucleoprotein K
- hnRNPUL1:
-
heterogeneous nuclear ribonucleoprotein U like 1
- HOTAIR:
-
lncRNA-HOX transcript antisense RNA
- HOTTIP:
-
lncRNA- HOXA distal transcript antisense RNA
- HR:
-
homologous recombination
- HULC:
-
hepatocellular carcinoma up-regulated long non-coding RNA
- ITPR1:
-
inositol 1,4,5-trisphosphate receptor type 1
- LBCS:
-
lncRNA-bladder cancer suppressor
- lncRNA:
-
long non-coding RNA
- LINP1:
-
lncRNA in nonhomologous end joining pathway 1
- LOL:
-
lncRNA of luminal
- MACC1-AS1:
-
lncRNA-metastasis-associated in colon cancer-antisense 1
- MALAT1:
-
lncRNA- metastasis associated lung adenocarcinoma transcript 1
- MAPK1:
-
mitogen-activated protein kinase 1
- MGMT:
-
O6-methylguanine DNA methyltransferase
- miRNA:
-
microRNA
- MDR:
-
multi-drug resistant protein
- MIZ1:
-
Myc-interacting zinc-finger protein-1
- MRP:
-
multidrug-Resistance like Protein 1, also known as ABCC1
- mTOR:
-
mammalian target of rapamycin
- MTX:
-
Methotrexate
- NSCLC:
-
non-small cell lung cancer
- NEAT1:
-
lncRNA- nuclear paraspeckle assembly transcript 1
- NGF:
-
nerve growth factor
- NHEJ:
-
non-homologous end joining
- NOXA:
-
phorbol-12-myristate-13-acetate-induced protein 1, also known as PMAIP1
- OR3A4:
-
lncRNA- olfactory receptor family 3 subfamily A member 4
- OXA:
-
oxaliplatin
- PANDAR:
-
promoter of CDKN1A antisense DNA damage activated RNA
- PARP-inhibitor:
-
poly ADP ribose polymerase inhibitor
- PIK3R3:
-
phosphoinositide-3-kinase regulatory subunit 3
- PGK1:
-
phosphoglycerate kinase 1
- PRC2:
-
polycomb repressive complex 2
- PTEN:
-
phosphatase and tensin homolog
- PTX:
-
paclitaxel
- PVT1:
-
lncRNA-plasmacytoma Variant Translocation 1
- RAD51-AS1:
-
lncRNA RAD51 antisense RNA 1
- Rb:
-
retinoblastoma
- ROR:
-
lncRNA-regulator of reprogramming
- RUNXOR:
-
RUNX1 overlapping lncRNA
- SFRS2:
-
splicing factor arginine/serine-rich 2
- SIRT1:
-
sirtuin 1
- SMAD2/3:
-
SMAD family member 2/3
- SNHG12:
-
lncRNA- small nucleolar RNA host gene 12
- SOX2:
-
SRY-box transcription factor 2
- STAT3:
-
signal transducer and activator of transcription 3
- TALC:
-
temozolomide-associated lncRNA in glioblastoma recurrence
- TF:
-
transcription factor
- TGF-β:
-
transforming growth factor beta
- TMZ:
-
Temozolomide
- TNBC:
-
triple-negative breast cancer
- TUG1:
-
taurine upregulated gene 1
- UCA1:
-
lncRNA- urothelial cancer associated 1
- ULK:
-
Unc-51 like autophagy activating kinase
- USP22:
-
ubiquitin specific peptidase 22
- VCR:
-
Vincristine
- VLDLR:
-
very low density lipoprotein receptor
- XIST:
-
X inactive specific transcript
- ZEB1 and 2:
-
zinc finger E-box binding homeobox 1 and 2
References
Miller, K. D., Nogueira, L., Mariotto, A. B., Rowland, J. H., Yabroff, K. R., Alfano, C. M., Jemal, A., Kramer, J. L., & Siegel, R. L. (2019). Cancer treatment and survivorship statistics, 2019. CA: a cancer journal for clinicians, 69, 363–385.
W.O. Rebecca, M.A. Richard, Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus, The Cochrane database of systematic reviews, (2003) Cd002092.
E. Wakeam, S.A. Acuna, N.B. Leighl, M.E. Giuliani, S.R.G. Finlayson, T.K. Varghese, G.E. Darling, Surgery versus chemotherapy and radiotherapy for early and locally advanced small cell lung cancer: a propensity-matched analysis of survival, Lung cancer (Amsterdam, Netherlands), 109 (2017) 78-88.
M.L. Ashdown, A.P. Robinson, S.L. Yatomi-Clarke, M.L. Ashdown, A. Allison, D. Abbott, S.N. Markovic, B.J. Coventry, Chemotherapy for late-stage cancer patients: meta-analysis of complete response rates, F1000Research, 4 (2015) 232.
Shewach, D. S., & Kuchta, R. D. (2009). Introduction to cancer chemotherapeutics. Chemical reviews, 109, 2859–2861.
Falzone, L., Salomone, S., & Libra, M. (2018). Evolution of cancer pharmacological treatments at the turn of the third millennium. Frontiers in pharmacology, 9, 1300.
Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014). Drug resistance in cancer: an overview. Cancers, 6, 1769–1792.
Swain, S. M. (2011). Chemotherapy: updates and new perspectives. The oncologist, 16(Suppl 1), 30–39.
Colombo, N., Lorusso, D., & Scollo, P. (2017). Impact of recurrence of ovarian cancer on quality of life and outlook for the future. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 27, 1134–1140.
Mansoori, B., Mohammadi, A., Davudian, S., Shirjang, S., & Baradaran, B. (2017). The different mechanisms of cancer drug resistance: a brief review. Advanced pharmaceutical bulletin, 7, 339–348.
Luqmani, Y. A. (2005). Mechanisms of drug resistance in cancer chemotherapy. Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 14(Suppl 1), 35–48.
T. Nunes, D. Hamdan, C. Leboeuf, M. El Bouchtaoui, G. Gapihan, T.T. Nguyen, S. Meles, E. Angeli, P. Ratajczak, H. Lu, M. Di Benedetto, G. Bousquet, A. Janin, Targeting cancer stem cells to overcome chemoresistance, International journal of molecular sciences, 19 (2018).
Sui, X., Chen, R., Wang, Z., Huang, Z., Kong, N., Zhang, M., Han, W., Lou, F., Yang, J., Zhang, Q., Wang, X., He, C., & Pan, H. (2013). Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell death & disease, 4, e838.
Kondo, Y., Shinjo, K., & Katsushima, K. (2017). Long non-coding RNAs as an epigenetic regulator in human cancers. Cancer science, 108, 1927–1933.
Schmitt, A. M., & Chang, H. Y. (2016). Long Noncoding RNAs in Cancer Pathways. Cancer cell, 29, 452–463.
Guttman, M., Donaghey, J., Carey, B. W., Garber, M., Grenier, J. K., Munson, G., Young, G., Lucas, A. B., Ach, R., Bruhn, L., Yang, X., Amit, I., Meissner, A., Regev, A., Rinn, J. L., Root, D. E., & Lander, E. S. (2011). lincRNAs act in the circuitry controlling pluripotency and differentiation. Nature, 477, 295–300.
Liu, K., Gao, L., Ma, X., Huang, J. J., Chen, J., Zeng, L., Ashby Jr., C. R., Zou, C., & Chen, Z. S. (2020). Long non-coding RNAs regulate drug resistance in cancer. Molecular cancer, 19, 54.
Wang, J., & Lindahl, T. (2016). Maintenance of genome stability. Genomics, proteomics & bioinformatics, 14, 119–121.
Tubbs, A., & Nussenzweig, A. (2017). Endogenous DNA damage as a source of genomic instability in cancer. Cell, 168, 644–656.
Nagel, Z. D., Kitange, G. J., Gupta, S. K., Joughin, B. A., Chaim, I. A., Mazzucato, P., Lauffenburger, D. A., Sarkaria, J. N., & Samson, L. D. (2017). DNA repair capacity in multiple pathways predicts chemoresistance in glioblastoma multiforme. Cancer research, 77, 198–206.
Brandsma, I., & Gent, D. C. (2012). Pathway choice in DNA double strand break repair: observations of a balancing act. Genome integrity, 3, 9.
Hosoya, N., & Miyagawa, K. (2014). Targeting DNA damage response in cancer therapy. Cancer science, 105, 370–388.
Zhang, Y., He, Q., Hu, Z., Feng, Y., Fan, L., Tang, Z., Yuan, J., Shan, W., Li, C., Hu, X., Tanyi, J. L., Fan, Y., Huang, Q., Montone, K., Dang, C. V., & Zhang, L. (2016). Long noncoding RNA LINP1 regulates repair of DNA double-strand breaks in triple-negative breast cancer. Nature structural & molecular biology, 23, 522–530.
X. Wang, H. Liu, L. Shi, X. Yu, Y. Gu, X. Sun, LINP1 facilitates DNA damage repair through non-homologous end joining (NHEJ) pathway and subsequently decreases the sensitivity of cervical cancer cells to ionizing radiation, Cell cycle (Georgetown, Tex.), 17 (2018) 439-447.
Wu, P., Cai, J., Chen, Q., Han, B., Meng, X., Li, Y., Li, Z., Wang, R., Lin, L., Duan, C., Kang, C., & Jiang, C. (2019). Lnc-TALC promotes O(6)-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nature communications, 10, 2045.
C.C. Chen, C.Y. Chen, S.H. Wang, C.T. Yeh, S.C. Su, S.H. Ueng, W.Y. Chuang, C. Hsueh, T.H. Wang, Melatonin sensitizes hepatocellular carcinoma cells to chemotherapy through long non-coding RNA RAD51-AS1-mediated suppression of DNA repair, Cancers, 10 (2018).
Sharma, V., Khurana, S., Kubben, N., Abdelmohsen, K., Oberdoerffer, P., Gorospe, M., & Misteli, T. (2015). A BRCA1-interacting lncRNA regulates homologous recombination. EMBO reports, 16, 1520–1534.
Liu, Z., Sun, M., Lu, K., Liu, J., Zhang, M., Wu, W., De, W., Wang, Z., & Wang, R. (2013). The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregualtion of p21(WAF1/CIP1) expression. PloS one, 8, e77293.
Wang, H., Fang, L., Jiang, J., Kuang, Y., Wang, B., Shang, X., Han, P., Li, Y., Liu, M., Zhang, Z., & Li, P. (2018). The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation. Cell death & disease, 9, 1103.
Gao, H., Song, X., Kang, T., Yan, B., Feng, L., Gao, L., Ai, L., Liu, X., Yu, J., & Li, H. (2017). Long noncoding RNA CRNDE functions as a competing endogenous RNA to promote metastasis and oxaliplatin resistance by sponging miR-136 in colorectal cancer. OncoTargets and therapy, 10, 205–216.
Modok, S., Mellor, H. R., & Callaghan, R. (2006). Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Current opinion in pharmacology, 6, 350–354.
Sharom, F. J. (2008). ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics, 9, 105–127.
Abbasifarid, E., Sajjadi-Jazi, S. M., Beheshtian, M., Samimi, H., Larijani, B., & Haghpanah, V. (2019). The role of ATP-binding cassette transporters in the chemoresistance of anaplastic thyroid cancer: a systematic review. Endocrinology, 160, 2015–2023.
Schondorf, T., Neumann, R., Benz, C., Becker, M., Riffelmann, M., Gohring, U. J., Sartorius, J., von Konig, C. H., Breidenbach, M., Valter, M. M., Hoopmann, M., Di Nicolantonio, F., & Kurbacher, C. M. (2003). Cisplatin, doxorubicin and paclitaxel induce mdr1 gene transcription in ovarian cancer cell lines. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 161, 111–116.
E.L. Christie, S. Pattnaik, J. Beach, A. Copeland, N. Rashoo, S. Fereday, J. Hendley, K. Alsop, S.L. Brady, G. Lamb, A. Pandey, A. deFazio, H. Thorne, A. Bild, D.D.L. Bowtell, Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer, Nature communications, 10 (2019) 1295.
Gao, H., Hao, G., Sun, Y., Li, L., & Wang, Y. (2018). Long noncoding RNA H19 mediated the chemosensitivity of breast cancer cells via Wnt pathway and EMT process. OncoTargets and therapy, 11, 8001–8012.
Zhu, Q. N., Wang, G., Guo, Y., Peng, Y., Zhang, R., Deng, J. L., Li, Z. X., & Zhu, Y. S. (2017). LncRNA H19 is a major mediator of doxorubicin chemoresistance in breast cancer cells through a cullin4A-MDR1 pathway. Oncotarget, 8, 91990–92003.
Tsang, W. P., & Kwok, T. T. (2007). Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells. Oncogene, 26, 4877–4881.
Jiang, P., Wang, P., Sun, X., Yuan, Z., Zhan, R., Ma, X., & Li, W. (2016). Knockdown of long noncoding RNA H19 sensitizes human glioma cells to temozolomide therapy. OncoTargets and therapy, 9, 3501–3509.
Shi, C., & Wang, M. (2018). LINC01118 Modulates Paclitaxel Resistance of Epithelial Ovarian Cancer by Regulating miR-134/ABCC1. Medical science monitor : international medical journal of experimental and clinical research, 24, 8831–8839.
Wang, J., Ye, C., Liu, J., & Hu, Y. (2018). UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis. Biochemical and biophysical research communications, 501, 1034–1040.
B. Ding, W. Lou, L. Xu, W. Fan, Non-coding RNA in drug resistance of hepatocellular carcinoma, Bioscience reports, 38 (2018).
Huang, H., Chen, J., Ding, C. M., Jin, X., Jia, Z. M., & Peng, J. (2018). LncRNA NR2F1-AS1 regulates hepatocellular carcinoma oxaliplatin resistance by targeting ABCC1 via miR-363. Journal of cellular and molecular medicine, 22, 3238–3245.
Takahashi, K., Yan, I. K., Wood, J., Haga, H., & Patel, T. (2014). Involvement of extracellular vesicle long noncoding RNA (linc-VLDLR) in tumor cell responses to chemotherapy. Molecular cancer research : MCR, 12, 1377–1387.
Z. Fang, W. Chen, Z. Yuan, X. Liu, H. Jiang, LncRNA-MALAT1 contributes to the cisplatin-resistance of lung cancer by upregulating MRP1 and MDR1 via STAT3 activation, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 101 (2018) 536-542.
X. Wu, Y. Zheng, B. Han, X. Dong, Long noncoding RNA BLACAT1 modulates ABCB1 to promote oxaliplatin resistance of gastric cancer via sponging miR-361, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 99 (2018) 832-838.
Abraham, R. T. (2001). Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes & development, 15, 2177–2196.
Bartek, J., & Lukas, J. (2003). Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer cell, 3, 421–429.
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008). DNA repair pathways as targets for cancer therapy. Nature reviews. Cancer, 8, 193–204.
Adriaens, C., Standaert, L., Barra, J., Latil, M., Verfaillie, A., Kalev, P., Boeckx, B., Wijnhoven, P. W., Radaelli, E., Vermi, W., Leucci, E., Lapouge, G., Beck, B., van den Oord, J., Nakagawa, S., Hirose, T., Sablina, A. A., Lambrechts, D., Aerts, S., Blanpain, C., & Marine, J. C. (2016). p53 induces formation of NEAT1 lncRNA-containing paraspeckles that modulate replication stress response and chemosensitivity. Nature medicine, 22, 861–868.
Shin, V. Y., Chen, J., Cheuk, I. W., Siu, M. T., Ho, C. W., Wang, X., Jin, H., & Kwong, A. (2019). Long non-coding RNA NEAT1 confers oncogenic role in triple-negative breast cancer through modulating chemoresistance and cancer stemness. Cell death & disease, 10, 270.
Lu, Y., Hu, Z., Mangala, L. S., Stine, Z. E., Hu, X., Jiang, D., Xiang, Y., Zhang, Y., Pradeep, S., Rodriguez-Aguayo, C., Lopez-Berestein, G., DeMarzo, A. M., Sood, A. K., Zhang, L., & Dang, C. V. (2018). MYC Targeted long noncoding RNA DANCR promotes cancer in part by reducing p21 Levels. Cancer research, 78, 64–74.
Lu, C., Wei, Y., Wang, X., Zhang, Z., Yin, J., Li, W., Chen, L., Lyu, X., Shi, Z., Yan, W., & You, Y. (2020). DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma. Molecular cancer, 19, 28.
Shang, J., Xu, Y. D., Zhang, Y. Y., & Li, M. (2019). Long noncoding RNA OR3A4 promotes cisplatin resistance of non-small cell lung cancer by upregulating CDK1. European review for medical and pharmacological sciences, 23, 4220–4225.
Jiang, H., Xiong, W., Chen, L., Lv, Z., Yang, C., & Li, Y. (2019). Knockdown of the long noncoding RNA HOTTIP inhibits cell proliferation and enhances cell sensitivity to cisplatin by suppressing the Wnt/beta-catenin pathway in prostate cancer. Journal of cellular biochemistry, 120, 8965–8974.
Sun, W., Xu, X., Jiang, Y., Jin, X., Zhou, P., Liu, Y., Guo, Y., Ma, D., Zuo, W., Huang, S., He, X., & Shao, Z. (2019). Transcriptome analysis of luminal breast cancer reveals a role for LOL in tumor progression and tamoxifen resistance. International journal of cancer, 145, 842–856.
Zuo, W., Zhang, W., Xu, F., Zhou, J., & Bai, W. (2019). Long non-coding RNA LINC00485 acts as a microRNA-195 sponge to regulate the chemotherapy sensitivity of lung adenocarcinoma cells to cisplatin by regulating CHEK1. Cancer cell international, 19, 240.
Liu, M., Zhang, H., Li, Y., Wang, R., Li, Y., Zhang, H., Ren, D., Liu, H., Kang, C., & Chen, J. (2018). HOTAIR, a long noncoding RNA, is a marker of abnormal cell cycle regulation in lung cancer. Cancer science, 109, 2717–2733.
G. Mor, M.K. Montagna, A.B. Alvero, Modulation of apoptosis to reverse chemoresistance, Methods in molecular biology (Clifton, N.J.), 414 (2008) 1-12.
Fraser, M., Leung, B., Jahani-Asl, A., Yan, X., Thompson, W. E., & Tsang, B. K. (2003). Chemoresistance in human ovarian cancer: the role of apoptotic regulators. Reproductive biology and endocrinology : RB&E, 1, 66.
Fridman, J. S., & Lowe, S. W. (2003). Control of apoptosis by p53. Oncogene, 22, 9030–9040.
Wong, R. S. (2011). Apoptosis in cancer: from pathogenesis to treatment. Journal of experimental & clinical cancer research : CR, 30, 87.
Han, J., Han, B., Wu, X., Hao, J., Dong, X., Shen, Q., & Pang, H. (2018). Knockdown of lncRNA H19 restores chemo-sensitivity in paclitaxel-resistant triple-negative breast cancer through triggering apoptosis and regulating Akt signaling pathway. Toxicology and applied pharmacology, 359, 55–61.
Si, X., Zang, R., Zhang, E., Liu, Y., Shi, X., Zhang, E., Shao, L., Li, A., Yang, N., Han, X., Pan, B., Zhang, Z., Sun, L., & Sun, Y. (2016). LncRNA H19 confers chemoresistance in ERα-positive breast cancer through epigenetic silencing of the pro-apoptotic gene BIK. Oncotarget, 7, 81452–81462.
Wang, F., Zhou, J., Xie, X., Hu, J., Chen, L., Hu, Q., Guo, H., & Yu, C. (2015). Involvement of SRPK1 in cisplatin resistance related to long non-coding RNA UCA1 in human ovarian cancer cells. Neoplasma.
Pan, J., Li, X., Wu, W., Xue, M., Hou, H., Zhai, W., & Chen, W. (2016). Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells. Cancer letters, 382, 64–76.
Chen, X., Liu, M., Meng, F., Sun, B., Jin, X., & Jia, C. (2019). The long noncoding RNA HIF1A-AS2 facilitates cisplatin resistance in bladder cancer. Journal of cellular biochemistry, 120, 243–252.
Du, P., Hu, C., Qin, Y., Zhao, J., Patel, R., Fu, Y., Zhu, M., Zhang, W., & Huang, G. (2019). LncRNA PVT1 Mediates Antiapoptosis and 5-Fluorouracil Resistance via Increasing Bcl2 Expression in Gastric Cancer. Journal of oncology, 2019, 9325407.
Yue, B., Cai, D., Liu, C., Fang, C., & Yan, D. (2016). Linc00152 functions as a competing endogenous RNA to confer oxaliplatin resistance and holds prognostic values in colon cancer. Molecular therapy : the journal of the American Society of Gene Therapy, 24, 2064–2077.
Nieto, M. A., Huang, R. Y., Jackson, R. A., & Thiery, J. P. (2016). EMT: 2016. Cell, 166, 21–45.
van Staalduinen, J., Baker, D., Ten Dijke, P., & van Dam, H. (2018). Epithelial-mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer? Oncogene, 37, 6195–6211.
Zhang, H. Y., Liang, F., Zhang, J. W., Wang, F., Wang, L., & Kang, X. G. (2017). Effects of long noncoding RNA-ROR on tamoxifen resistance of breast cancer cells by regulating microRNA-205. Cancer chemotherapy and pharmacology, 79, 327–337.
Chen, Y. M., Liu, Y., Wei, H. Y., Lv, K. Z., & Fu, P. (2016). Linc-ROR induces epithelial-mesenchymal transition and contributes to drug resistance and invasion of breast cancer cells. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 37, 10861–10870.
An, J., Lv, W., & Zhang, Y. (2017). LncRNA NEAT1 contributes to paclitaxel resistance of ovarian cancer cells by regulating ZEB1 expression via miR-194. OncoTargets and therapy, 10, 5377–5390.
Li, P., Zhang, X., Wang, H., Wang, L., Liu, T., Du, L., Yang, Y., & Wang, C. (2017). MALAT1 Is Associated with poor response to oxaliplatin-based chemotherapy in colorectal cancer patients and promotes chemoresistance through EZH2. Molecular cancer therapeutics, 16, 739–751.
Jia, J., Zhan, D., Li, J., Li, Z., Li, H., & Qian, J. (2019). The contrary functions of lncRNA HOTAIR/miR-17-5p/PTEN axis and Shenqifuzheng injection on chemosensitivity of gastric cancer cells. Journal of cellular and molecular medicine, 23, 656–669.
Glick, D., Barth, S., & Macleod, K. F. (2010). Autophagy: cellular and molecular mechanisms. The Journal of pathology, 221, 3–12.
Colhado Rodrigues, B. L., Lallo, M. A., & Perez, E. C. (2020). The controversial role of autophagy in tumor development: a systematic review. Immunological investigations, 49, 386–396.
Kim, J., Kundu, M., Viollet, B., & Guan, K. L. (2011). AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nature cell biology, 13, 132–141.
Mizushima, N. (2019). The ATG conjugation systems in autophagy. Current opinion in cell biology, 63, 1–10.
Zhang, W., Liu, Y., Fu, Y., Han, W., Xu, H., Wen, L., Deng, Y., & Liu, K. (2020). Long non-coding RNA LINC00160 functions as a decoy of microRNA-132 to mediate autophagy and drug resistance in hepatocellular carcinoma via inhibition of PIK3R3. Cancer letters, 478, 22–33.
Cai, Q., Wang, S., Jin, L., Weng, M., Zhou, D., Wang, J., Tang, Z., & Quan, Z. (2019). Long non-coding RNA GBCDRlnc1 induces chemoresistance of gallbladder cancer cells by activating autophagy. Molecular cancer, 18, 82.
Wang, M., Han, D., Yuan, Z., Hu, H., Zhao, Z., Yang, R., Jin, Y., Zou, C., Chen, Y., Wang, G., Gao, X., & Wang, X. (2018). Long non-coding RNA H19 confers 5-Fu resistance in colorectal cancer by promoting SIRT1-mediated autophagy. Cell death & disease, 9, 1149.
YiRen, H., YingCong, Y., Sunwu, Y., Keqin, L., Xiaochun, T., Senrui, C., Ende, C., XiZhou, L., & Yanfan, C. (2017). Long noncoding RNA MALAT1 regulates autophagy associated chemoresistance via miR-23b-3p sequestration in gastric cancer. Molecular cancer, 16, 174.
Xiong, H., Ni, Z., He, J., Jiang, S., Li, X., He, J., Gong, W., Zheng, L., Chen, S., Li, B., Zhang, N., Lyu, X., Huang, G., Chen, B., Zhang, Y., & He, F. (2017). LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells. Oncogene, 36, 3528–3540.
Xu, S., Wang, P., Zhang, J., Wu, H., Sui, S., Zhang, J., Wang, Q., Qiao, K., Yang, W., Xu, H., & Pang, D. (2019). Ai-lncRNA EGOT enhancing autophagy sensitizes paclitaxel cytotoxicity via upregulation of ITPR1 expression by RNA-RNA and RNA-protein interactions in human cancer. Molecular cancer, 18, 89.
Quintana, E., Shackleton, M., Foster, H. R., Fullen, D. R., Sabel, M. S., Johnson, T. M., & Morrison, S. J. (2010). Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer cell, 18, 510–523.
Kim, Y., Joo, K. M., Jin, J., & Nam, D. H. (2009). Cancer stem cells and their mechanism of chemo-radiation resistance. International journal of stem cells, 2, 109–114.
Ntziachristos, P., Abdel-Wahab, O., & Aifantis, I. (2016). Emerging concepts of epigenetic dysregulation in hematological malignancies. Nature immunology, 17, 1016–1024.
Lohitesh, K., Chowdhury, R., & Mukherjee, S. (2018). Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight. Cancer cell international, 18, 44.
Wang, H., Li, W., Guo, R., Sun, J., Cui, J., Wang, G., Hoffman, A. R., & Hu, J. F. (2014). An intragenic long noncoding RNA interacts epigenetically with the RUNX1 promoter and enhancer chromatin DNA in hematopoietic malignancies. International journal of cancer, 135, 2783–2794.
Chen, X., Xie, R., Gu, P., Huang, M., Han, J., Dong, W., Xie, W., Wang, B., He, W., Zhong, G., Chen, Z., Huang, J., & Lin, T. (2019). Long noncoding RNA LBCS inhibits self-renewal and chemoresistance of bladder cancer stem cells through epigenetic silencing of SOX2. Clinical cancer research : an official journal of the American Association for Cancer Research, 25, 1389–1403.
He, W., Liang, B., Wang, C., Li, S., Zhao, Y., Huang, Q., Liu, Z., Yao, Z., Wu, Q., Liao, W., Zhang, S., Liu, Y., Xiang, Y., Liu, J., & Shi, M. (2019). MSC-regulated lncRNA MACC1-AS1 promotes stemness and chemoresistance through fatty acid oxidation in gastric cancer. Oncogene, 38, 4637–4654.
Katsushima, K., Natsume, A., Ohka, F., Shinjo, K., Hatanaka, A., Ichimura, N., Sato, S., Takahashi, S., Kimura, H., Totoki, Y., Shibata, T., Naito, M., Kim, H. J., Miyata, K., Kataoka, K., & Kondo, Y. (2016). Targeting the Notch-regulated non-coding RNA TUG1 for glioma treatment. Nature communications, 7, 13616.
Funding
This study was supported by a research program of P-CREATE, Japan Agency for Medical Research and Development (Y. Kondo), and of the Grant-in-Aid for Scientific Research, the Japan Society for the Promotion of Science (Y. Kondo)
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Peng, Y., Tang, D., Zhao, M. et al. Long non-coding RNA: A recently accentuated molecule in chemoresistance in cancer. Cancer Metastasis Rev 39, 825–835 (2020). https://doi.org/10.1007/s10555-020-09910-w
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10555-020-09910-w